featured-image

AUSTIN, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary second quarter 2024 OvaSuite product volume and highlights. “Our OvaSuite product volume, and in particular our OvaWatch volume, has grown each month since the beginning of the year, demonstrating that the commercial changes we made last year are having a positive impact,” said Nicole Sandford, Chief Executive Officer of Aspira.

“The data showing OvaWatch’s clinical effectiveness is resonating with physicians and payers alike. We believe that OvaWatch, which at this early stage already represents 20% of total volume, will be a key component of Aspira’s future growth. The release of the periodic monitoring feature in May radically increased the size of the test’s addressable market to between 2 and 4 million tests a year.



Armed with a mature and effective sales force and strong clinical data, the momentum is clearly building.” Ms. Sandford added, “We continue to be laser focused on cash management.

Earlier this week, we announced the closing of an at-the-market private placement with gross proceeds of nearly $1.9 million with many of our largest shareholders and company insiders demonstrating their support of the Company. As mentioned in our June update, we anticipate providing a downward revi.

Back to Health Page